文献速递儿童青少年精神物质与行为成瘾心境障碍

2018至2022年美国行为健康药物新发处方趋势

Trends in Incident Prescriptions for Behavioral Health Medications in the US, 2018-2022.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

本研究基于IQVIA国家处方审计数据,分析2018年4月至2022年3月美国门诊药房五种行为健康药物新发处方趋势。结果显示,新冠疫情期间多数药物新发处方相对稳定,但注意缺陷多动障碍(ADHD)药物尤其是C-II兴奋剂急剧增加,且执业护士开具的所有药物类别新发处方增幅最大。

要点

  • 新冠疫情期间ADHD药物新发处方显著上升,C-II兴奋剂趋势变化为每月4007张处方(95%CI 1592-6422)。
  • 执业护士开具的所有药物类别新发处方增幅最大,范围从7%(苯二氮䓬类)到78%(丁丙诺啡MOUD)。
  • 抗抑郁药、苯二氮䓬类和丁丙诺啡MOUD的新发处方趋势在疫情期间无显著变化。

核心结论

  • 新冠疫情期间美国多数行为健康药物新发处方保持相对稳定,但ADHD药物尤其是C-II兴奋剂新发处方急剧增加。
  • 需要进一步研究区分ADHD药物增加是源于未满足的需求还是过度处方,并强调需制定ADHD指南以界定治疗适当性。

研究设计与样本

  • 横断面研究,使用IQVIA国家处方审计的全面、人口层面、全国预测数据。
  • 分析2018年4月至2022年3月美国门诊药房五种药物类别的新发处方(患者既往12个月内未从同一药物类别配药)。
  • 采用中断时间序列分析比较月度新发处方趋势变化和 aggregate 新发处方百分比变化。

主要发现

  • 丁丙诺啡MOUD显著下降(水平变化-2915张处方[95%CI -5513至-318]),但丁丙诺啡MOUD、抗抑郁药和苯二氮䓬类的趋势无显著变化。

临床怎么用

  • 临床医生应关注ADHD药物尤其是C-II兴奋剂新发处方的快速增长,评估治疗适当性。
  • 执业护士在行为健康药物处方中的作用增强,需关注其处方模式和质量。

局限性

  • 研究为观察性设计,无法区分处方增加是源于未满足需求还是过度处方。
  • 数据仅反映新发处方,未涉及患者临床结局或治疗适当性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The COVID-19 pandemic reportedly increased behavioral health needs and impacted treatment access. OBJECTIVE: To assess changes in incident prescriptions dispensed for medications commonly used to treat depression, anxiety, attention-deficit/hyperactivity disorder (ADHD), and opioid use disorder (OUD), before and during the COVID-19 pandemic. DESIGN, SETTING, AND PARTICIPANTS: This was a cross-sectional study using comprehensive, population-level, nationally projected data from IQVIA National Prescription Audit on incident prescriptions (prescriptions dispensed to patients with no prior dispensing from the same drug class in the previous 12 months) dispensed for antidepressants, benzodiazepines, Schedule II (C-II) stimulants, nonstimulant medications for ADHD, and buprenorphine-containing medication for OUD (MOUD), from US outpatient pharmacies. Data were analyzed from April 2018 to March 2022. EXPOSURE: Incident prescriptions by drug class (by prescriber specialty, patient age, and sex) and drug. MAIN OUTCOMES AND MEASURES: Interrupted time-series analysis to compare changes in trends in the monthly incident prescriptions dispensed by drug class and percentage changes in aggregate incident prescriptions dispensed between April 2018 and March 2022. RESULTS: Incident prescriptions dispensed for the 5 drug classes changed from 51 500 321 before the COVID-19 pandemic to 54 000 169 during the pandemic. The largest unadjusted percentage increase in incident prescriptions by prescriber specialty was among nurse practitioners across all drug classes ranging from 7% (from 1 811 376 to 1 944 852; benzodiazepines) to 78% (from 157 578 to 280 925; buprenorphine MOUD), whereas for patient age and sex, the largest increases were within C-II stimulants and nonstimulant ADHD drugs among patients aged 20 to 39 years (30% [from 1 887 017 to 2 455 706] and 81% [from 255 053 to 461 017], respectively) and female patients (25% [from 2 352 095 to 2 942 604] and 59% [from 395 678 to 630 678], respectively). Trends for C-II stimulants and nonstimulant ADHD drugs (slope change: 4007 prescriptions per month; 95% CI, 1592-6422 and 1120 prescriptions per month; 95% CI, 706-1533, respectively) significantly changed during the pandemic, exceeding prepandemic trends after an initial drop at the onset of the pandemic (level changes: -50 044 prescriptions; 95% CI, -80 202 to -19 886 and -12 876 prescriptions; 95% CI, -17 756 to -7996, respectively). Although buprenorphine MOUD dropped significantly (level change: -2915 prescriptions; 95% CI, -5513 to -318), trends did not significantly change for buprenorphine MOUD, antidepressants, or benzodiazepines. CONCLUSIONS AND RELEVANCE: Incident use of many behavioral health medications remained relatively stable during the COVID-19 pandemic in the US, whereas ADHD medications, notably C-II stimulants, sharply increased. Additional research is needed to differentiate increases due to unmet need vs overprescribing, highlighting the need for further ADHD guideline development to define treatment appropriateness.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Chai G, Xu J, Goyal S, et al. Trends in Incident Prescriptions for Behavioral Health Medications in the US, 2018-2022. JAMA Psychiatry. 2024. PMID: 38198145. doi:10.1001/jamapsychiatry.2023.5045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。